Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined Analysis

Abstract

Cytoreductive nephrectomy appears to improve significantly overall survival in patients with metastatic renal cancer treated with interferon immunotherapy independent of patient performance status, the site of metastases and the presence of measurable disease. Although it is highly statistically significant, the overall survival advantage is only 5.8 months for the entire group. These data emphasize the need to determine if this survival advantage can be further improved using more aggressive immunotherapy or other novel agents in the setting of cytoreductive nephrectomy.

Keywords

MedicineNephrectomyRandomizationClinical endpointInternal medicineRandomized controlled trialAlpha interferonKidney cancerOncologyRenal cell carcinomaCancerSurgeryPerformance statusUrologyInterferonKidneyImmunology

Affiliated Institutions

Related Publications

Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer

Robert C. Flanigan , Sydney E. Salmon , Brent A. Blumenstein +6 more

Nephrectomy followed by interferon therapy results in longer survival among patients with metastatic renal-cell cancer than does interferon therapy alone.

2001 New England Journal of Medicine 1719 citations

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

Thomas Powles , Se Hoon Park , Éric Voog +24 more

Maintenance avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who h...

2020 New England Journal of Medicine 1374 citations

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

Yohann Loriot , Andrea Necchi , Se Hoon Park +18 more

The use of erdafitinib was associated with an objective tumor response in 40% of previously treated patients who had locally advanced and unresectable or metastatic urothelial c...

2019 New England Journal of Medicine 1277 citations

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

Hedy L. Kindler , Donna Niedzwiecki , Donna Hollis +12 more

Purpose The combination of gemcitabine plus bevacizumab produced a 21% response rate and a median survival of 8.8 months in a multicenter phase II trial in patients with metasta...

2010 Journal of Clinical Oncology 834 citations

Treatment of muscle‐invasive and advanced bladder cancer in 2020

Vaibhav G. Patel , William Oh , Matthew D. Galsky

Abstract Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades, the systemic management of muscle‐invasive and advanced bladder cancer has pri...

2020 CA A Cancer Journal for Clinicians 1092 citations

Publication Info

Year: 2004
Type: article
Volume: 171
Issue: 3
Pages: 1071-1076
Citations: 869
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined Analysis

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

869

OpenAlex

Cite This

APA Style

                            
                                
                                    Robert C. Flanigan, 
                                
                                    G. Mickisch, 
                                
                                    Richard Sylvester
                                
                                et al.
                            
                            (2004). 
                            Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined Analysis. 
                            The Journal of Urology
                            , 171
                            (3)
                            , 1071-1076.
                            https://doi.org/10.1097/01.ju.0000110610.61545.ae
                        

Identifiers

DOI: 10.1097/01.ju.0000110610.61545.ae